As reported (here) previously, the stem cell treatment for ALS from Israel’s Brainstorm is doing well in trials.  The latest Phase 2 trial of Brainstorm’s autologous bone-marrow derived MSC-NTF cells (Nurown) in 48 patients at 3 US sites was effective and well tolerated.

http://ir.brainstorm-cell.com/news-releases/news-release-details/brainstorm-cell-therapeutics-announces-publication-nurownr-als